

Rev03 DATASHEET

Update: Dec,14,2021

SARS-CoV-2 Spike protein (S1, E484K, K417T, N501Y, His Tag)

Cat. No.: Z03602

Product Introduction

| Species | SARS-CoV-2 | | |
|------------------------------|---|----------|--|
| Protein Construction | Expressed with the mutations of E484K, K417T, N501Y. | | |
| | S1 protein (Gln14-Arg685) Accession # P0DTC2 | Poly-His | |
| | N-term | C-term | |
| Purity | > 95% as analyzed by SDS-PAGE | | |
| Endotoxin Level | $<$ 0.2 EU/ μg of protein by gel clotting method | | |
| Biological Activity | This protein is validated to bind with human ACE2 in functional ELISA assay. | | |
| Expression System | СНО | | |
| Theoretical Molecular Weight | 75.7 kDa | | |
| Formulation | Supplied as a solution in PBS, pH 7.4. | | |
| Concentration | Please refer to the COA for the specific lot. | | |
| Storage & Stability | Upon receiving, this product remains stable for up to 6 months at -20°C or below. Please avoid repeated freeze-thaw cycles. | | |

Background

Target Background: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Lineage P.1, also known as the Brazil(ian) variant is one of the variants of SARS-CoV-2. This variant has 17 amino acid changes, ten of which are in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T. SARS-CoV-2 Spike protein (S1, E484K, K417T, N501Y, His Tag) carries a polyhistidine tag at the C-terminus.

Synonyms: Lineage P.1; 20J/501Y.V3; VOC-202101/02; Brazil(ian) variant; Gamma variant

References:

- 1. Variants: distribution of cases data. GOV.UK. Retrieved 27 February 2021.
- 2. COVID-19: Virologist says Brazilian coronavirus variant detected in UK is not the one 'of concern'.
- 3. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings.

GenScript USA, Inc.



| For laboratory research use only. Direct human use, including taking orally and injection and clir orbidden. | nical use are |
|---|---------------|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |